• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Transl Med . Potential inhibitors for blocking the interaction of the coronavirus SARS-CoV-2 spike protein and its host cell receptor ACE2

tetano

Editor, Senior Moderator
J Transl Med


. 2022 Jul 14;20(1):314.
doi: 10.1186/s12967-022-03501-9.
Potential inhibitors for blocking the interaction of the coronavirus SARS-CoV-2 spike protein and its host cell receptor ACE2


Changzhi Li[SUP] #[/SUP][SUP] 1 2 [/SUP], Hongjuan Zhou[SUP] #[/SUP][SUP] 3 [/SUP], Lingling Guo[SUP] #[/SUP][SUP] 1 [/SUP], Dehuan Xie[SUP] 1 [/SUP], Huiping He[SUP] 1 4 [/SUP], Hong Zhang[SUP] 1 [/SUP], Yixiu Liu[SUP] 3 [/SUP], Lixia Peng[SUP] 1 [/SUP], Lisheng Zheng[SUP] 1 [/SUP], Wenhua Lu[SUP] 1 [/SUP], Yan Mei[SUP] 1 [/SUP], Zhijie Liu[SUP] 1 [/SUP], Jie Huang[SUP] 3 [/SUP], Mingdian Wang[SUP] 1 [/SUP], Ditian Shu[SUP] 1 [/SUP], Liuyan Ding[SUP] 1 [/SUP], Yanhong Lang[SUP] 1 [/SUP], Feifei Luo[SUP] 1 [/SUP], Jing Wang[SUP] 1 [/SUP], Bijun Huang[SUP] 1 [/SUP], Peng Huang[SUP] 1 [/SUP], Song Gao[SUP] 5 6 [/SUP], Jindong Chen[SUP] 7 [/SUP], Chao-Nan Qian[SUP] 8 9 10 [/SUP]



Affiliations

Abstract

Background: The outbreak of SARS-CoV-2 continues to pose a serious threat to human health and social. The ongoing pandemic of COVID-19 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has made a serious threat to public health and economic stability worldwide. Given the urgency of the situation, researchers are attempting to repurpose existing drugs for treating COVID-19.
Methods: We first established an anti-coronavirus drug screening platform based on the Homogeneous Time Resolved Fluorescence (HTRF) technology and the interaction between the coronavirus spike protein and its host receptor ACE2. Two compound libraries of 2,864 molecules were screened with this platform. Selected candidate compounds were validated by SARS-CoV-2_S pseudotyped lentivirus and ACE2-overexpressing cell system. Molecular docking was used to analyze the interaction between S protein and compounds.
Results: We identified three potential anti-coronavirus compounds: tannic acid (TA), TS-1276 (anthraquinone), and TS-984 (9-Methoxycanthin-6-one). Our in vitro validation experiments indicated that TS-984 strongly inhibits the interaction of the coronavirus S protein and the human cell ACE2 receptor. Additionally, tannic acid showed moderate inhibitory effect on the interaction of S protein and ACE2.
Conclusion: This platform is a rapid, sensitive, specific, and high throughput system, and available for screening large compound libraries. TS-984 is a potent blocker of the interaction between the S-protein and ACE2, which might have the potential to be developed into an effective anti-coronavirus drug.

Keywords: 9-Methoxycanthin-6-one; ACE2; COVID-19; Coronavirus; SARS-CoV-2; Spike protein; Tannic acid.
 
Back
Top Bottom